Novogene(SH:688315)2022-04-26 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥386,628,023.16, representing a year-on-year increase of 5.83%[6] - The net profit attributable to shareholders of the listed company was ¥18,866,423.65, a decrease of 42.66% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,381,188.53, reflecting a slight increase of 2.30% year-on-year[6] - Basic and diluted earnings per share were both ¥0.05, down 44.44% year-on-year[9] - Net profit for Q1 2022 was CNY 20,012,365.86, a decrease of 40.8% from CNY 33,619,210.00 in Q1 2021[39] - Operating profit for Q1 2022 was CNY 22,255,507.84, down 41.5% from CNY 37,916,476.22 in Q1 2021[37] - Total comprehensive income for Q1 2022 was CNY 16,743,883.58, down from CNY 35,621,664.65 in Q1 2021[39] Cash Flow - The net cash flow from operating activities was -¥186,140,305.10, indicating a significant cash outflow[9] - Cash flow from operating activities for Q1 2022 was negative CNY 186,140,305.10, compared to negative CNY 139,732,903.79 in Q1 2021[44] - The net cash flow from investing activities was -$44.34 million, a decrease from $80.12 million in the previous period[46] - Cash inflow from financing activities totaled $52 million, compared to $12 million in the prior period[46] - The net cash flow from financing activities was -$4.29 million, a significant improvement from -$42.87 million previously[46] - The net decrease in cash and cash equivalents was -$240.82 million, worsening from -$103.28 million in the previous period[46] - The ending balance of cash and cash equivalents was $650.15 million, down from $890.98 million at the beginning of the period[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,597,284.93, a decrease of 3.91% from the end of the previous year[9] - Current assets totaled approximately ¥1.74 trillion, down from ¥1.91 trillion, indicating a decrease of around 8.9%[32] - Cash and cash equivalents were reported at ¥651.55 million, a significant drop from ¥897.84 million, representing a decline of approximately 27.4%[29] - Accounts receivable increased to ¥578.95 million from ¥527.59 million, marking an increase of about 9.7%[29] - Total liabilities were approximately ¥929.57 million, down from ¥1.06 billion, reflecting a decrease of about 12.4%[34] - Shareholders' equity totaled approximately ¥1.82 billion, an increase from ¥1.80 billion, indicating a growth of about 1.4%[34] Research and Development - Research and development expenses totaled ¥25,549,842.88, which is 6.61% of operating revenue, down by 1.04 percentage points year-on-year[9] - Research and development expenses for Q1 2022 were CNY 21,864,425.24, a decrease of 22% from CNY 27,956,011.94 in Q1 2021[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,256[17] - The company reported a total of ¥6,485,235.12 in non-recurring gains and losses for the period[10]